EUVIMEDEUVIMED entdecken
Crossref

Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series

Hanna Bonnekoh, Lea Kiefer, Thomas Buttgereit, Pavel Kolkhir, Marie Lütke-Eversloh, Jörg Scheffel, Marcus Maurer, Martin Metz

The Journal of Allergy and Clinical Immunology: In Practice · 2023

DOI: 10.1016/j.jaip.2023.05.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Hanna Bonnekoh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin…. Hauptthemen laut MEDLINE: Chronic Urticaria, Anti-Allergic Agents, Urticaria. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaAnti-Allergic AgentsUrticariaHumansOmalizumabAntibodies, Monoclonal, HumanizedChronic DiseaseTreatment Outcome

Substanzen

OmalizumabtildrakizumabAntibodies, Monoclonal, HumanizedAnti-Allergic Agents

Autor:innen und Institutionen

  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Transl…

Zitieren

APA

Bonnekoh, H., Kiefer, L., Buttgereit, T., Kolkhir, P., Lütke-Eversloh, M., Scheffel, J., Maurer, M., & Metz, M. (2023). Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.05.019

Vancouver

Bonnekoh H, Kiefer L, Buttgereit T, Kolkhir P, Lütke-Eversloh M, Scheffel J, et al. Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.05.019

BibTeX
@article{Bonnekoh2023,
  author = {Bonnekoh, Hanna and Kiefer, Lea and Buttgereit, Thomas and Kolkhir, Pavel and Lütke-Eversloh, Marie and Scheffel, Jörg and Maurer, Marcus and Metz, Martin},
  title = {Anti–IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  doi = {10.1016/j.jaip.2023.05.019}
}
Kostenlos starten →